Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 physician-initiated RE-01 cell therapy for non-healing lower extremity ulcers
jRCT2033220413Phase 1Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Dec 2022
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RE-01 in lower extremity ulcer, Buerger disease (TAO), systemic sclerosis (SSc) and 11 more, sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Primary safety endpoints. Started Dec 2022; status: completed.
02
Drugs
RE-01
03
Conditions
lower extremity ulcerBuerger disease (TAO)systemic sclerosis (SSc)systemic lupus erythematosus (SLE)dermatomyositis (DM)
Beyond the preview
Go deeper on jRCT2033220413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033220413.